Update on the biology and therapy of gastrointestinal stromal tumors

Cancer Control

Volumn 12, Issue 1, 2005, Pages 44-56

  D'Amato, Gina ^a   Steinert, Dejka M ^b   McAuliffe, John C ^b   Trent, Jonathan C ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CAFFEINE; CISPLATIN; CLINDAMYCIN; CLONAZEPAM; DACARBAZINE; DOXORUBICIN; ETHINYLESTRADIOL; HYDROCORTISONE; HYPERICUM PERFORATUM EXTRACT; IFOSFAMIDE; IMATINIB; IRINOTECAN; MITOMYCIN; MITOXANTRONE; OBLIMERSEN; PARACETAMOL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; VERAPAMIL;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; BLEEDING; CELL VIABILITY; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG POTENTIATION; DYSPEPSIA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; INTERSTITIAL CELL OF CAJAL; LACRIMATION; MALIGNANT TRANSFORMATION; MESENCHYMOMA; MYALGIA; NAUSEA; NEUTROPENIA; PACEMAKER; PHOTOSENSITIVITY DISORDER; RASH; REVIEW; TASTE DISORDER; VISUAL IMPAIRMENT; VOMITING;

EID: 12744274526     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480501200106     Document Type: Review

References (95)

1. Clary BM, DeMatteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol. 2001;8:290-299.
2. KindBlom LG, Meis-Kindblom JM, Bumming P. Incidence, prevalence, phenotype and biologic sectrum of gastrointestinal stromal cell tumors (GIST): a population-based study of 600 cases. Ann Oncol. 2002;13(suppl 5):157. Abstract 5770.
3. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507-519.
4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
5. Carney JA, Sheps SG, Go VL, et al. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med. 1977;296:1517-1518.
6. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clinic Proc. 1999;74:543-552.
7. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology. 2002;122:1493-1499.
8. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology. 2001;120:210-215.
9. Hirota S, Okazaki T, Kitamura Y, et al. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol. 2000;24:326-327.
10. Isozaki K, Terris B, Belghiti J, et al. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol. 2000;157:1581-1585.
11. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet. 1998;19:323-324.
12. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res. 2003;9:13-19. Epub 2003 Apr 18.
13. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Intl J Surg Pathol. 2002;10:81-89.
14. Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000;13:577-585.
15. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23:1109-1118.
16. Fleischman RA. From white spots to stem cells: the role of the Kit receptor in mammalian development. Trends Genet. 1993;9:285-290.
17. Kluppel M, Huizinga JD, Malysz J, et al. Developmental origin and Kit-dependent development of the interstitial cells of cajal in the mammalian small intestine. Dev Dyn. 1998;211:60-71.
18. Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol. 2000;13:536-541.
19. Miettinen M, Virolainen M, Maarit-Sarlomo-Rikala. Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995;19:207-216.
20. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728-734.
21. Chirieac L, Trent J, Steinert DM, et al. Correlation of immunophenotype with clinical outcome of GIST patients treated with imatinib mesylate. Presented at the 9th Annual Connective Tissue Oncology Society, November 6-8, 2003, Barcelona.
22. Miettinen M. Are desmoid tumors kit positive? Am J Surg Pathol. 2001;25:549-550.
23. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging. Ann Surg. 1992;215:68-77.
24. Al-Bozom IA. p53 expression in gastrointestinal stromal tumors. Pathol Int 2001;51:519-523.
25. Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol. 2002;33:669-676.
26. Takahashi R, Tanaka S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology. 2003;64:266-274.
27. Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol. 2003;21:1688-1697.
28. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297-4300.
29. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol. 1999;154:53-60.
30. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002;160:1567-1572.
31. Rubin BP, Singer S, Tsao C, et al. KIT activation is a u7biquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118-8121.
32. Trent JC II, McConkey DJ, Loughlin SM, et al. Ras signaling in tumor necrosis factor-induced apoptosis. EMBO J. 1996;15:4497-4505.
33. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
34. Majumder S, Brown K, Qiu FH, et al. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol. 1988;8:4896-4903.
35. Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am. 2000;14:517-535.
36. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, et al. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. Embo J. 1991;10:4121-4128.
37. Isozaki K, Hirota S, Nakama A, et al. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology. 1995;109:456-464.
38. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92:1736-1744.
39. Rottapel R, Reedijk M, Williams DE, et al. The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol Cell Biol. 1991;11:3043-3051.
40. Tauchi T, Feng GS, Marshall MS, et al. The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells. J Biol Chem. 1994;269:25206-25211.
41. Gommerman JL, Sittaro D, Klebasz NZ, et al. Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential. Blood. 2000;96:3734-3742.
42. Cutler RL, Liu L, Damen JE, et al. Multiple cytokines induce the tyrosine phosphorylation of She and its association with Grb2 in hemopoietic cells. J Biol Chem. 1993;268:21463-21465.
43. Lev S, Givol D, Yarden Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J. 1991;10:647-654.
44. Yi T, Ihle JN. Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. Mol Cell Biol. 1993;13:3350-3358.
45. Blume-Jensen P, Ronnstrand L, Gout I, et al. Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C. J Biol Chem. 1994;269:21793-21802.
46. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484-495.
47. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology. 1998;115:1090-1095.
48. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-3905.
49. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
50. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689-695.
51. Ma Y, Cunningham ME, Wang X, et al. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem. 1999;274:13399-13402.
52. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64:5913-5919.
53. Gottlieb JA, Baker LH, O'Bryan RM, et al. Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep Part 3. 1975;6:271-282.
54. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003;98:2693-2699.
55. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58.
56. Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer. 2002;94:2441-2446.
57. DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001;234:540-548.
58. Mavligit GM, Zukiwski AA, Salem PA, et al. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer. 1991;68:321-323.
59. Mavligit GM, Zukwiski AA, Ellis LM, et al. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer. 1995;75:2083-2088.
60. Eilber FC, Rosen G, Forscher C, et al. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol. 1999;6:645-650.
61. Plager C, Papadoupolos NE, Salem P, et al. Adriamycin-based chemotherapy for leiomyosarcoma of the stomach and small intestine. Proc Annu Meet Am Soc Clin Oncol. 1991;10:352.
62. Patel SR, Legha SS, Salem PA, et al. Evaluation of ifosfamide in metastatic leiomyosarcomas of GI origin. Proc Annu Meet Am Soc Clin Oncol. 1991;31:352. Abstract 1252.
63. Edmonson J, Marks R, Buckner J, et al. Contrast of response D-MAP plus sargramostin between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Annu Meet Am Soc Clin Oncol. 1999;18. Abstract 541.
64. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
65. Lydon NB, Druker BJ. Lessons learned from the development of imatinib. Leuk Res. 2004;28:S29-38.
66. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 2002;346:683-693.
67. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
68. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
69. Trent JC, Hannay JA, Li L, et al. Inhibition of PDGF-R signaling by Gleevec (STI-571) in huma rhabdomyosarcoma cell lines. J Princess Takamatsu Symposia. 2001;32:16-29.
70. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
71. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
72. Druker BJ, Talpez M, Resta DJ. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
73. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI-571) for GIST: Intergroup S0033 early results. Proc Annu Meet Am Soc Clin Oncol. 2003. Abstract 3271.
74. Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117). Proc Annu Meet Am Soc Clin Oncol. 2001. Abstract 1.
75. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
76. von Mehren M, Blanke C, Joensuu H, et al. High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs). Proc Annu Meet Am Soc Clin Oncol. 2002. Abstract 1608.
77. Van Oosterom A, Judson I, Verweij J. STI57, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study. Proc Annu Meet Am Soc Clin Oncol. 2001. Abstract 2.
78. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004;44:158-162.
79. Ie Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol. 2004;53:313-323.
80. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother. 2003;4:963-971.
81. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer. 2003;89:1855-1859.
82. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76:323-329.
83. Avramis IA, Laug WE, Sausville EA, et al. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol. 2003;52:307-318. Epub 2003 Jun 25.
84. Joensuu H, Roberts PJ, Sartomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
85. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
86. Verweij J, Casali J, Zalcberg A, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG, and AGITG. Proc Annu Meet Am Soc Clin Oncol. 2003. Abstract 3272.
87. Rankin C, von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - a phase III sarcoma group study S0033. Proc Annu Meet Am Soc Clin Oncol. 2004. Abstract 9005.
88. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
89. Casali PG, Verweij J, Zalcberg A, et al. Imatinib (Glivec) 400 vs 800 mg daily in patients with gastrointestinal stromal tumors (GIST): a randomized phase III trial from the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group (ISG) and the Australasian Gastrointestinal Trials Group (AGITG). A toxicity report. Proc Annu Meet Am Soc Clin Oncol. 2002. Abstract 1650.
90. Trent J. A Prospective, Randomized, Phase II Study of Preoperative Plus Postoperative Imatinib Mesylate (Gleevec, Formerly STI-571) in Patients With Primary, Recurrent, or Metastatic Resectable, Kit-Expressing, Gastrointestinal Stromal Tumor (GIST). Available at http://utmext01a.mdacc.tmc.edu/dept/prot/ clinicaltrialswp.nsf/Index/ID03-0023. Accessed December 8, 2004.
91. Trent J. A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117) (ACRIN 6665). Available at http://utm-ext01a. mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/RTOG%20S0132. Accessed December 8, 2004.
92. Davis DW, Buchholz TA, Hess KR, et al. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003;9:955-960.
93. Patel S. A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST). Available at http://utmext01a.mdacc.tmc. edu/dept/prot/clinicaltrialswp.nsf/Index/ID02-491. Accessed December 8, 2004.
94. Herbst RS. A Phase I, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects with Advanced Solid Tumors. Available at http://utm-ext01a.mdacc.tmc.edu/dept/prot/ clinicaltrialswp.nsf/Index/2003-0460. Accessed December 8, 2004.
95. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006-2011.